Drug Profile
CLS 005
Alternative Names: CLS005Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Cutanea Life Sciences
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rosacea
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-III for Rosacea (Topical) (Cutanea Life Sciences website, February 2022)
- 08 Dec 2016 Phase-III clinical trials in Rosacea (Topical)